Design Therapeutics, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Design Therapeutics, Inc. (DSGN) reported Increase (Decrease) in Prepaid Expense and Other Assets of $678.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-03
- Design Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $391.00K.
- Design Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $287.00K, a 79.60% decline year-over-year.
- Design Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $880.00K.
- Design Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$459.00K.
- Design Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $1.38M.
- Design Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$226.00K.
- Design Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$1.97M, a 158.18% decline from fiscal 2022.
- Design Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $3.39M, a 233.63% increase from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $391.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $678.00K 10-Q · filed 2026-08-03 | $1.56M derived: sum of 3 quarters · filed 2026-08-03 | $1.10M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $287.00K 10-Q · filed 2026-04-28 | $1.17M derived: sum of 2 quarters · filed 2026-04-28 | $708.00K derived: sum of 3 quarters · filed 2026-04-28 | $256.00K derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $880.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $421.00K derived: sum of 2 quarters · filed 2026-03-09 | -$31.00K derived: sum of 3 quarters · filed 2026-08-03 | $1.38M 10-K · filed 2026-03-09 |
| 2025-09-30 | -$459.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$911.00K derived: sum of 2 quarters · filed 2026-08-03 | $496.00K 10-Q · filed 2025-11-05 | -$109.00K derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | -$452.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $955.00K 10-Q · filed 2026-08-03 | $350.00K derived: sum of 3 quarters · filed 2026-08-03 | -$310.00K derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $1.41M 10-Q · filed 2026-04-28 | $802.00K derived: sum of 2 quarters · filed 2026-04-28 | $142.00K derived: sum of 3 quarters · filed 2026-04-28 | $770.00K derived: sum of 4 quarters · filed 2026-04-28 |
| 2024-12-31 | -$605.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$1.26M derived: sum of 2 quarters · filed 2026-03-09 | -$637.00K derived: sum of 3 quarters · filed 2026-03-09 | -$226.00K 10-K · filed 2026-03-09 |
| 2024-09-30 | -$660.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$32.00K derived: sum of 2 quarters · filed 2025-11-05 | $379.00K 10-Q · filed 2025-11-05 | -$444.00K derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $628.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $1.04M 10-Q · filed 2025-08-07 | $216.00K derived: sum of 3 quarters · filed 2025-08-07 | $855.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $411.00K 10-Q · filed 2025-05-07 | -$412.00K derived: sum of 2 quarters · filed 2025-05-07 | $227.00K derived: sum of 3 quarters · filed 2025-05-07 | -$371.00K derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | -$823.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$184.00K derived: sum of 2 quarters · filed 2025-03-10 | -$782.00K derived: sum of 3 quarters · filed 2025-03-10 | -$1.97M 10-K · filed 2025-03-10 |
| 2023-09-30 | $639.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $41.00K derived: sum of 2 quarters · filed 2024-11-07 | -$1.15M 10-Q · filed 2024-11-07 | -$680.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$598.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | -$1.79M 10-Q · filed 2024-08-05 | -$1.32M derived: sum of 3 quarters · filed 2024-08-05 | $583.00K derived: sum of 4 quarters · filed 2024-08-05 |
| 2023-03-31 | -$1.19M 10-Q · filed 2024-05-08 | -$721.00K derived: sum of 2 quarters · filed 2024-05-08 | $1.18M derived: sum of 3 quarters · filed 2024-05-08 | $964.00K derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $471.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $2.37M derived: sum of 2 quarters · filed 2024-03-19 | $2.16M derived: sum of 3 quarters · filed 2024-03-19 | $3.39M 10-K · filed 2024-03-19 |
| 2022-09-30 | $1.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $1.69M derived: sum of 2 quarters · filed 2023-11-13 | $2.92M 10-Q · filed 2023-11-13 | $2.78M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$217.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $1.02M 10-Q · filed 2023-08-14 | $879.00K derived: sum of 3 quarters · filed 2023-08-14 | $413.00K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $1.24M 10-Q · filed 2023-05-09 | $1.10M derived: sum of 2 quarters · filed 2023-05-09 | $630.00K derived: sum of 3 quarters · filed 2023-05-09 | |
| 2021-12-31 | -$141.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | -$607.00K derived: sum of 2 quarters · filed 2023-03-14 | $1.02M 10-K · filed 2023-03-14 | |
| 2021-09-30 | -$466.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $1.16M 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | $1.62M 10-Q · filed 2022-08-08 | |||
| 2020-12-31 | $270.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $298.00K derived: sum of 2 quarters · filed 2022-03-10 | $335.00K derived: sum of 3 quarters · filed 2022-03-10 | $341.00K 10-K · filed 2022-03-10 |
| 2020-09-30 | $28.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $65.00K derived: sum of 2 quarters · filed 2021-11-09 | $71.00K 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $37.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $43.00K 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $6.00K 10-Q · filed 2021-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |